Coherus Oncology, Inc. (CHRS) P/E Ratio History
Historical price-to-earnings valuation from 2019 to 2024
Loading P/E history...
Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of March 2, 2026, Coherus Oncology, Inc. (CHRS) trades at a price-to-earnings ratio of 6.7x, with a stock price of $1.67 and trailing twelve-month earnings per share of $1.33.
The current P/E is 31% below its 5-year average of 9.8x. Over the past five years, CHRS's P/E has ranged from a low of 7.6x to a high of 15.1x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.7x, CHRS trades at a 72% discount to its sector peers. The sector includes 224 companies with P/E ratios ranging from 0.0x to 184.4x.
Relative to the broader market, CHRS trades at a notable discount to the S&P 500 median P/E of 26.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our CHRS DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
Peer Comparison
P/E metrics vs. Oncology Therapeutics Developers peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
INCYIncyte Corporation | $20B | 15.8 | - | +4173%Best |
GMABGenmab A/S | $18B | 15.4 | 0.53 | +84% |
EXELExelixis, Inc. | $12B | 15.8 | 0.31Best | +58% |
INBXInhibrx Biosciences, Inc. | $1B | 0.6Lowest | - | +2377% |
BBOTBridgeBio Oncology Therapeutics Inc. | $794M | 21.8 | - | - |
PBYIPuma Biotechnology, Inc. | $287M | 9.3 | - | -2% |
CHRSCoherus Oncology, Inc. | $194M | 6.7 | - | +110% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
Historical P/E Data
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2024 Q4 | $1.38 | $0.18 | 7.8x | -20% | |
| FY2020 Q4 | $17.38 | $1.63 | 10.7x | +9% | |
| FY2020 Q3 | Wed Sep 30 2020 00:00:00 GM | $18.34 | $2.04 | 9.0x | -8% |
| FY2020 Q2 | $17.86 | $2.34 | 7.6x | -22% | |
| FY2020 Q1 | $16.22 | $1.96 | 8.3x | -15% | |
| FY2019 Q4 | $18.00 | $1.19 | 15.1x | +55% |
Average P/E for displayed period: 9.8x
See CHRS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CHRS Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare CHRS vs AGIO
See how CHRS stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is CHRS stock overvalued or undervalued?
CHRS trades at 6.7x P/E, below its 5-year average of 9.8x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does CHRS's valuation compare to peers?
Coherus Oncology, Inc. P/E of 6.7x compares to sector median of 23.7x. The discount suggests lower growth expectations or higher risk.
What is CHRS's PEG ratio?
CHRS PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2019-2024.